Syndax Pharmaceuticals Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report (Form 8-K) covers the results of the Annual Meeting of Stockholders held by Syndax Pharmaceuticals, Inc. on May 11, 2022. The filing details the voting outcomes for four proposals submitted to shareholders.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
The following proposals were voted upon at the Annual Meeting:
- Proposal 1 (Election of Directors): All three nominees were elected to serve three-year terms.
- Keith A. Katkin: 27,678,960 For; 16,421,107 Withheld.
- Briggs W. Morrison, M.D.: 25,378,018 For; 18,722,049 Withheld.
- Dennis G. Podlesak: 23,356,637 For; 20,743,430 Withheld.
- Proposal 2 (Say-on-Pay): Shareholders approved the compensation of named executive officers on an advisory basis.
- For: 43,865,366
- Against: 226,947
- Abstain: 7,754
- Proposal 3 (Say-on-Pay Frequency): Shareholders recommended an annual frequency for future advisory votes on executive compensation.
- 1 Year: 43,352,824
- 2 Years: 4,886
- 3 Years: 685,702
Consequently, the Board determined to hold future Say-on-Pay votes annually until the next frequency vote, no later than the 2028 annual meeting.
- Proposal 4 (Ratification of Auditors): Shareholders ratified the selection of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2022.
- For: 49,190,850
- Against: 16,961
- Abstain: 759
Guidance, Outlook, and Risks
The filing text does not provide management commentary on business outlook, financial guidance, risks, contingencies, or unusual items. It is strictly a report of shareholder voting outcomes.
Investor Verification Checklist
- Verify the specific terms of the three-year director terms for the newly elected board members.
- Confirm the implementation of the annual Say-on-Pay frequency as decided by the Board.
- Review the definitive proxy statement filed on March 29, 2022, for detailed descriptions of the proposals and executive compensation data.
- Note that this filing contains no financial metrics; refer to the most recent 10-K or 10-Q for financial health indicators.